ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Reduced Leaflet Motion After Transcatheter Aortic Valve Replacement

Friday, November 22, 2019

Submitted by

Aristotle Protopapas

Source

Source Name: The New England Journal of Medicine

Source URL: https://www.nejm.org/doi/full/10.1056/NEJMoa1911426

Author(s)

Ole De Backer, George D. Dangas, Hasan Jilaihawi, Jonathon A. Leipsic, Christian J. Terkelsen, Raj Makkar, Annapoorna S. Kini, Karsten T. Veien, Mohamed Abdel-Wahab, Won-Keun Kim, Prakash Balan, Nicolas Van Mieghem, Ole N. Mathiassen, Raban V. Jeger, Martin Arnold, Roxana Mehran, Ana H.C. Guimarães, Bjarne L. Nørgaard, Klaus F. Kofoed, Philipp Blanke, Stephan Windecker, and Lars Søndergaard, M.D., D.M.Sc. for the GALILEO-4D Investigators Abstract

Puzzling subgroup from the GALILEO trial, which appears in the same issue of the periodical as an article that discredits the use of rivaroxaban as thromboprevention strategy :

https://www.nejm.org/doi/full/10.1056/NEJMoa1911425?query=recirc_curatedRelated_article,

And yet, in this particular subgroup, a subclinical benefit on leaflet mobility is being suggested! It would appear that the GALILEO will be discussed at length and in detail in the months and years to come.